(NASDAQ: AKYA) Akoya Biosciences's forecast annual revenue growth rate of 12.54% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.2%.
Akoya Biosciences's revenue in 2024 is $93,216,000.On average, 4 Wall Street analysts forecast AKYA's revenue for 2024 to be $4,851,444,721, with the lowest AKYA revenue forecast at $4,766,800,598, and the highest AKYA revenue forecast at $4,942,622,776. On average, 3 Wall Street analysts forecast AKYA's revenue for 2025 to be $5,790,152,992, with the lowest AKYA revenue forecast at $5,669,671,241, and the highest AKYA revenue forecast at $6,013,296,680.
In 2026, AKYA is forecast to generate $6,883,349,163 in revenue, with the lowest revenue forecast at $6,667,580,899 and the highest revenue forecast at $7,249,546,368.